Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability.
暂无分享,去创建一个
Barbara A. Wetmore | R. Woodrow Setzer | John F. Wambaugh | Robert G. Pearce | Caroline L. Ring | J. Wambaugh | R. Setzer | B. Wetmore | Robert G Pearce | C. Ring | Caroline L Ring
[1] Amin Rostami-Hodjegan,et al. Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.
[2] D. Hattis,et al. Pharmacokinetic and Pharmacodynamic Factors That Can Affect Sensitivity to Neurotoxic Sequelae in Elderly Individuals , 2005, Environmental health perspectives.
[3] Basic anatomical and physiological data for use in radiological protection: the skeleton. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. , 1995, Annals of the ICRP.
[4] Amin Rostami-Hodjegan,et al. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[5] Vicki L Burt,et al. National health and nutrition examination survey: sample design, 2011-2014. , 2014, Vital and health statistics. Series 2, Data evaluation and methods research.
[6] Kevin McNally,et al. PopGen: A virtual human population generator. , 2014, Toxicology.
[7] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[8] Wilfried De Backer,et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. , 2006, Metabolism: clinical and experimental.
[9] W. Slob,et al. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry , 2012, Critical reviews in toxicology.
[10] Harvey J Clewell,et al. Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.
[11] Dion R. Brocks,et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery , 2008, Nature Reviews Drug Discovery.
[12] G. L. Kedderis,et al. Incorporating human interindividual biotransformation variance in health risk assessment. , 2002, The Science of the total environment.
[13] H. McLeod,et al. Genetic basis of drug metabolism. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[14] K Rowland-Yeo,et al. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[15] R. Poland,et al. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross‐ethnic comparative study , 2006, Clinical pharmacology and therapeutics.
[16] D. Belle,et al. Genetic factors in drug metabolism. , 2008, American family physician.
[17] Y. Sugiyama,et al. Inter-individual variability of in vivo CYP2D6 activity in different genotypes. , 2012, Drug metabolism and pharmacokinetics.
[18] Ann M Richard,et al. Linking high resolution mass spectrometry data with exposure and toxicity forecasts to advance high-throughput environmental monitoring. , 2016, Environment international.
[19] Ruili Huang,et al. Population-Based in Vitro Hazard and Concentration–Response Assessment of Chemicals: The 1000 Genomes High-Throughput Screening Study , 2015, Environmental health perspectives.
[20] Shumei S. Guo,et al. 2000 CDC Growth Charts for the United States: methods and development. , 2002, Vital and health statistics. Series 11, Data from the National Health Survey.
[21] Z H Israili,et al. HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡ , 2001, Drug metabolism reviews.
[22] John C Lipscomb,et al. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment , 2001, Toxicology and industrial health.
[23] Thomas Lumley,et al. Analysis of Complex Survey Samples , 2004 .
[24] L Zhang,et al. The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies , 2008, Clinical pharmacology and therapeutics.
[25] P. Prusis,et al. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[26] M. Jamei,et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.
[27] M. Hiratsuka. In vitro assessment of the allelic variants of cytochrome P450. , 2012, Drug metabolism and pharmacokinetics.
[28] J. Valentin. Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.
[29] D. Hattis,et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[30] Lester R Curtin,et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. , 2013, Vital and health statistics. Series 2, Data evaluation and methods research.
[31] Paul S Price,et al. Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.
[32] Paola Annoni,et al. Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index , 2010, Comput. Phys. Commun..
[33] J. Shepherd,et al. Total body bone area, bone mineral content, and bone mineral density for individuals aged 8 years and over: United States, 1999-2006. , 2013, Vital and health statistics. Series 11, Data from the National Health Survey.
[34] Franco Lombardo,et al. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.
[35] Robert G. Pearce,et al. httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.
[36] G. Schwartz,et al. Measurement and estimation of GFR in children and adolescents. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[37] K. Neville,et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. , 2006, The oncologist.
[38] Harvey J. Clewell,et al. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.
[39] Y. Sugiyama,et al. Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. , 2010, Drug metabolism and pharmacokinetics.
[40] R. Barr,et al. Age- and gender-dependent values of skeletal muscle mass in healthy children and adolescents , 2011, Journal of cachexia, sarcopenia and muscle.
[41] Imran Shah,et al. Toxicokinetic Triage for Environmental Chemicals. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[42] G. Tucker,et al. Incorporation of Inter-Individual Variability into the Prediction of In Vivo Drug Clearance from In Vitro Data , 2006 .
[43] Dean P. Jones,et al. High-performance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoring. , 2012, Toxicology.
[44] David M. Reif,et al. High-throughput models for exposure-based chemical prioritization in the ExpoCast project. , 2013, Environmental science & technology.
[45] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[46] R. Judson,et al. High throughput heuristics for prioritizing human exposure to environmental chemicals. , 2014, Environmental science & technology.
[47] P. Routledge. The plasma protein binding of basic drugs. , 1986, British journal of clinical pharmacology.
[48] John C Lipscomb,et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.
[49] Arnaud Tonnelier,et al. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model , 2011, Archives of Toxicology.
[50] K. Flegal,et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. , 2014, JAMA.
[51] Robert J Kavlock,et al. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[52] Harvey J Clewell,et al. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.
[53] I. Ijiri,et al. A statistical analysis of the internal organ weights of normal Japanese people. , 1997, Health physics.
[54] G R Wilkinson,et al. Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.
[55] W. Slikker,et al. Incorporating children's toxicokinetics into a risk framework. , 2004, Environmental health perspectives.
[56] Melvin E. Andersen,et al. Incorporating New Technologies Into Toxicity Testing and Risk Assessment: Moving From 21st Century Vision to a Data-Driven Framework , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[57] L. Grummer-Strawn,et al. Use of World Health Organization and CDC Growth Charts for Children Aged 0–59 Months in the United States (Excerpt) , 2010, Clinical Lactation.
[58] David M. Reif,et al. Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. , 2012, Chemical research in toxicology.
[59] R. Judson,et al. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. , 2011, Chemical research in toxicology.
[60] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[61] Walter Schmitt,et al. Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[62] T. Mizutani. PM Frequencies of Major CYPs in Asians and Caucasians , 2003, Drug metabolism reviews.
[63] Melvin E. Andersen,et al. Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[64] R. Hines,et al. Ontogeny of human hepatic cytochromes P450 , 2007, Journal of biochemical and molecular toxicology.
[65] Weimin Sun,et al. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory , 2011, Genetics in Medicine.
[66] Robert J Kavlock,et al. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[67] Kristin Isaacs,et al. Estimating Sobol sensitivity indices using correlations , 2012, Environ. Model. Softw..
[68] Julien Jacques,et al. Sensitivity analysis in presence of model uncertainty and correlated inputs , 2006, Reliab. Eng. Syst. Saf..
[69] J. Lipscomb,et al. Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.
[70] Walter Schmitt,et al. General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.
[71] H. Pan,et al. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age , 2006 .
[72] G. Schwartz,et al. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. , 1978, The Journal of pediatrics.
[73] L. Teuschler,et al. Variance of Microsomal Protein and Cytochrome P450 2E1 and 3A Forms in Adult Human Liver , 2003, Toxicology mechanisms and methods.
[74] Sean M Hays,et al. Consideration of dosimetry in evaluation of ToxCast™ data , 2011, Journal of applied toxicology : JAT.
[75] D. Bailey,et al. Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone mass , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[76] Y. Sugiyama,et al. Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans. , 2014, Drug metabolism and pharmacokinetics.
[77] W. Koo,et al. Body composition in human infants at birth and postnatally. , 2000, The Journal of nutrition.